The UK Health Security Agency (UKHSA) is set to introduce a new RSV vaccination program for pregnant women in September, which could prevent approximately 5,000 hospitalizations and 15,000 emergency department visits for infants annually. The program is based on a study predicting that if 60% of pregnant women receive the vaccine, it could reduce RSV illnesses in infants by 70,000 and lower GP consultations by 20,000. RSV is a significant health threat, causing severe respiratory conditions and accounting for 20 to 30 infant deaths each year in the UK. In Scotland, a similar initiative has been launched, investing £4.2 million to vaccinate pregnant women and those aged 75 and over, emphasizing the importance of vaccination to ease winter pressures on healthcare. Research indicates that the new RSV vaccine does not elevate the risk of preterm birth or adverse perinatal outcomes, which encourages broader acceptance among expectant mothers. Health officials urge eligible individuals to take advantage of the program to protect vulnerable populations from RSV-related illnesses.